BioCentury | Jul 9, 2020
Finance

July 8 Quick Takes: CapitalBio raises $113M, plans Shanghai IPO; plus Aidea, CF PharmTech, Denovo, Nucleai and Vaxdyn

...included new investors BioTrack Capital, CICC Qichen, CICC Qide, SAIC Hengxu, GP M&A Fund and Watson Investment...
BioCentury | Oct 11, 2010
Finance

moksha8 Sees Profit

moksha8 sees profit Last week's series D financing and deal with Watson Pharmaceuticals Inc. (NYSE:WPI), has given specialty pharma moksha8 Pharmaceuticals Inc. its first branded generic products and enough cash to get it to profitability,...
BioCentury | Oct 11, 2010
Company News

moksha8, Watson sales and marketing update

Watson will manufacture and supply 12 undisclosed products to moksha8, which will have exclusive rights to market, sell and distribute these products in Brazil and Mexico. Watson will continue to own all marketing authorizations, but...
Items per page:
1 - 3 of 3
BioCentury | Jul 9, 2020
Finance

July 8 Quick Takes: CapitalBio raises $113M, plans Shanghai IPO; plus Aidea, CF PharmTech, Denovo, Nucleai and Vaxdyn

...included new investors BioTrack Capital, CICC Qichen, CICC Qide, SAIC Hengxu, GP M&A Fund and Watson Investment...
BioCentury | Oct 11, 2010
Finance

moksha8 Sees Profit

moksha8 sees profit Last week's series D financing and deal with Watson Pharmaceuticals Inc. (NYSE:WPI), has given specialty pharma moksha8 Pharmaceuticals Inc. its first branded generic products and enough cash to get it to profitability,...
BioCentury | Oct 11, 2010
Company News

moksha8, Watson sales and marketing update

Watson will manufacture and supply 12 undisclosed products to moksha8, which will have exclusive rights to market, sell and distribute these products in Brazil and Mexico. Watson will continue to own all marketing authorizations, but...
Items per page:
1 - 3 of 3